EP3969117
KRISTÖLLUÐ FORM AF N-[4-(KLÓRDÍFLÚORMETOXÝ)FENÝL]-6-[(3R)-3-HÝDROXÝPYRRÓLIDÍN-1-ÝL]-5-(1H-PÝRASÓL-5-ÝL)PÝRIDÍN-3-KARBOXAMÍÐI
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.5.2020EP published:
25.3.2026EP application number:
20726959.8
EP translation filed:
21.5.2026Grant published:
10.6.2026EPO information:
European Patent Register
Max expiry date:
14.5.2040Expiry date:
24.7.2026
Title in English:
CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDELanguage of the patent:
English
Timeline
Today
15.5.2020EP application
25.3.2026EP Publication
21.5.2026Translation submitted
10.6.2026Registration published
24.7.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
DODD, Stephanie KayAddress:
Cambridge, New Jersey 02139, US
Name:
GRANDEURY, ArnaudAddress:
4002 Basel, CH
Name:
ROUSAKI, EvgeniaAddress:
4002 Basel, CH
Name:
SUFFERT, EmmanuelAddress:
4002 Basel, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962848857 PDate:
16.5.2019Country:
US
Number:
201962949599 PDate:
18.12.2019Country:
US
Classification
Categories:
A61P 35/00, A61K 31/4439, C07D 401/14